104 related articles for article (PubMed ID: 38872043)
1. Impact of Presenting Stage on Overall Survival in Patients Treated with Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
Carroll JF; Hoskin TL; Leon-Ferre RA; Boughey JC
Ann Surg Oncol; 2024 Jun; ():. PubMed ID: 38872043
[TBL] [Abstract][Full Text] [Related]
2. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES
Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).
Weiss A; Campbell J; Ballman KV; Sikov WM; Carey LA; Hwang ES; Poppe MM; Partridge AH; Ollila DW; Golshan M
Ann Surg Oncol; 2021 Oct; 28(11):5960-5971. PubMed ID: 33821344
[TBL] [Abstract][Full Text] [Related]
6. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Sharma P; López-Tarruella S; García-Saenz JA; Khan QJ; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Monte-Millán MD; González-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortés J; Fuentes-Rivera H; Morales DB; Márquez-Rodas I; Perou CM; Lehn C; Wang YY; Klemp JR; Mammen JV; Wagner JL; Amin AL; O'Dea AP; Heldstab J; Jensen RA; Kimler BF; Godwin AK; Martín M
Clin Cancer Res; 2018 Dec; 24(23):5820-5829. PubMed ID: 30061361
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.
Bagegni NA; Tao Y; Ademuyiwa FO
PLoS One; 2019; 14(9):e0222358. PubMed ID: 31536530
[TBL] [Abstract][Full Text] [Related]
8. Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy.
Woriax HE; Thomas SM; Plichta JK; Rosenberger LH; Botty van den Bruele A; Chiba A; Hwang ES; DiNome ML
J Clin Oncol; 2024 May; 42(14):1635-1645. PubMed ID: 38394476
[TBL] [Abstract][Full Text] [Related]
9. Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients.
Gentile D; Sagona A; De Carlo C; Fernandes B; Barbieri E; Di Maria Grimaldi S; Jacobs F; Vatteroni G; Scardina L; Biondi E; Vinci V; Trimboli RM; Bernardi D; Tinterri C
Breast; 2023 Jun; 69():323-329. PubMed ID: 37001289
[TBL] [Abstract][Full Text] [Related]
10. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
[TBL] [Abstract][Full Text] [Related]
11. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
12. Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution.
Chen D; Wang Q; Dong M; Chen F; Huang A; Chen C; Lu Y; Zhao W; Wang L
BMC Cancer; 2023 Oct; 23(1):984. PubMed ID: 37845617
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer.
Wu L; Chen M; Lin Y; Zeng B; Guo W; Chen L; Li Y; Yu L; Li J; Chen X; Zhang W; Li S; Cai W; Zhang K; Jin X; Huang J; Lin Q; Yang Y; Fu F; Wang C
Am J Surg Pathol; 2024 Jan; 48(1):27-35. PubMed ID: 38117286
[TBL] [Abstract][Full Text] [Related]
14. Postmastectomy radiation therapy following pathologic complete nodal response to neoadjuvant chemotherapy: A prelude to NSABP B-51?
Haque W; Singh A; Verma V; Schwartz MR; Chevli N; Hatch S; Desai M; Butler EB; Arentz C; Farach A; Teh BS
Radiother Oncol; 2021 Sep; 162():52-59. PubMed ID: 34214615
[TBL] [Abstract][Full Text] [Related]
15. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy.
Krug D; Vladimirova V; Untch M; Kühn T; Schneeweiss A; Denkert C; Ataseven B; Solbach C; Gerber B; Tesch H; Golatta M; Seiler S; Heil J; Nekljudova V; Holtschmidt J; Loibl S
Breast; 2024 Apr; 74():103701. PubMed ID: 38422624
[TBL] [Abstract][Full Text] [Related]
16. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
Goorts B; van Nijnatten TJ; de Munck L; Moossdorff M; Heuts EM; de Boer M; Lobbes MB; Smidt ML
Breast Cancer Res Treat; 2017 May; 163(1):83-91. PubMed ID: 28205044
[TBL] [Abstract][Full Text] [Related]
17. Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.
Martín M; Yoder R; Salgado R; Del Monte-Millán M; Álvarez EL; Echavarría I; Staley JM; O'Dea AP; Nye LE; Stecklein SR; Bueno C; Jerez Y; Cebollero M; Bueno O; García Saenz JÁ; Moreno F; Bohn U; Gómez H; Massarrah T; Khan QJ; Godwin AK; López-Tarruella S; Sharma P
Clin Cancer Res; 2024 May; 30(10):2160-2169. PubMed ID: 38466643
[TBL] [Abstract][Full Text] [Related]
18. Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study.
de Wild SR; Koppert LB; de Munck L; Vrancken Peeters MTFD; Siesling S; Smidt ML; Simons JM
Breast Cancer Res Treat; 2024 Apr; 204(2):277-288. PubMed ID: 38133707
[TBL] [Abstract][Full Text] [Related]
19. Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy.
Wang Y; Zong B; Yu Y; Wang Y; Tang Z; Chen R; Huang M; Liu S
Front Oncol; 2021; 11():668610. PubMed ID: 34235079
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
